News | FDA | May 22, 2024

The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic, Inc. BioZorb marker due to complications with implanted devices. The agency identified this as a Class I recall, the most serious type of recall. Details issued in a written notice by the FDA on May 22 and are shared here.

The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic, Inc. BioZorb marker due to complications with implanted devices.

The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic, Inc. BioZorb marker due to complications with implanted devices. The agency identified this as a Class I recall, the most serious type of recall, in a May 22 written notice by the FDA shared here. Image courtesy: Hologic, Inc.


May 22, 2024 — The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic Inc. BioZorb marker due to complications with implanted devices. The agency identified this as a Class I recall, the most serious type of recall. Details issued in a written notice by the FDA on May 22 and are shared here.

The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Details on the recall were issued in a written notice by the FDA and are shared here in their entirety.

Please be aware, this recall is a correction, not a product removal. 

Recalled Product

Product Name: BioZorb Marker

Product Codes: NEU 

Model Numbers

F0405 BioZorb Marker 4cm x 5cm

F0404 BioZorb Marker 4cm x 4cm

F0331 BioZorb Marker 1cm x 3cm x 3cm

F0231 BioZorb Marker 1cm x 3cm x 2cm

F0221 BioZorb Marker 1cm x 3cm x 2cm

F0304 BioZorb Marker 3cm x 4cm

F0303 BioZorb Marker 3cm x 3cm

F0203 BioZorb Marker 2cm x 3cm

F0202 BioZorb Marker 2cm x 2cm

Distribution Dates: April 29, 2019 to April 1, 2024

Devices Recalled in the U.S.: 53,492

Date Initiated by Firm: March 13, 2024

Device Use

The BioZorb Marker made by Hologic (previously Focal Therapeutics), is an implantable radiographic marker used to mark soft tissue (such as breast tissue) for future medical procedures, such as radiation. Device has two components: a permanent component which is made of titanium metal and a resorbable component which is made of a plastic material that resorbes over time. It's provided sterile, meant for one-time use.

Reason for Recall  

Hologic, Inc. is recalling Biozorb Marker due to complications and adverse events reported with implanted devices. Complaints included reports of pain, infection, rash, device migration, device erosion, seroma, discomfort, or other complications from feeling the device in the breast, and the need for additional medical treatment to remove the device.

There have been 71 reported injuries and no reports of death.

Who May be Affected 

- People who were implanted with the BioZorb marker device.

- People who receive radiation guided by the BioZorb marker which may have migrated.

- People who receive systemic cancer treatments as treatments may be delayed due to complications with BioZorb Marker.

- Radiologist, surgeons, oncologists and other health care providers who use BioZorb Marker for treatment of their patients.

What to Do 

On March 13, 2024, Hologic, Inc. sent all affected customers an Important Medical Device Safety Notification.  

The letter requested patients to:

- Contact their health care provider if they experience any adverse events following the placement of a BioZorb Marker.

- Discuss the benefits and possible risks of implantable breast tissue markers for breast cancer procedures with their health care provider.

- Report any problems or complications experienced following the placement of BioZorb Marker devices to Hologic at [email protected] and to the FDA’s MedWatch Adverse Event Reporting program.

- Discuss the benefits and possible risks of implantable breast tissue markers for breast cancer procedures with their health care provider.

The letter requested health care providers to:

- Be aware of reports of serious adverse events following the placement of the BioZorb Marker devices in breast tissue.

- Discuss the benefits and possible risks of BioZorb Marker devices with each patient.

- Inform all patients on which device will be used if a marking device will be used during breast conservation surgery.

- Continue to monitor patients who have an implanted BioZorb Marker for signs of any adverse events.

Report any problems or complications experienced by patients following placement of the BioZorb Marker devices to Hologic

Complaints can be submitted to [email protected] and to the FDA’s MedWatch Adverse Event Reporting program.

Contact Information 

Customers in the U.S. with questions about this recall should contact Hologic, Inc. at [email protected].

Additional Resources

Class 1 Device Recall BioZorb LP Marker (fda.gov) 

BioZorb Markers and Potential Risks with Use in Breast Tissue: FDA Safety Communication | FDA

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX.


Related Content

News | Mobile C-Arms

June 19, 2024 —Royal Philips, a global leader in health technology, today announced the launch of Philips Image Guided ...

Time June 19, 2024
arrow
News | Breast Imaging

June 18, 2024 — Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue Breast ...

Time June 18, 2024
arrow
Feature | Imaging Technology News - ITN

Dear Friends and Readers of ITN, Can you spare 3 minutes today to give us some feedback? Please share your insight with ...

Time June 17, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | Neuro Imaging

June 12, 2024 — Brainet, a developer of cutting-edge diagnostic tools for assessing brain health, and SimonMed Imaging ...

Time June 12, 2024
arrow
News | SNMMI

June 11, 2024 — Heather Jacene, MD, assistant chief of Nuclear Medicine and Molecular Imaging at Brigham and Women’s ...

Time June 11, 2024
arrow
News | SNMMI

June 11, 2024 — The Society of Nuclear Medicine and Molecular Imaging recognized six new SNMMI Fellows during a plenary ...

Time June 11, 2024
arrow
News | Artificial Intelligence

June 6, 2024 — Sunway Medical Centre, Sunway City (SMC), the largest private quaternary hospital in Malaysia, embarks on ...

Time June 06, 2024
arrow
Subscribe Now